Yeda Research and Development

Dr. Elik Chapnik is a technology transfer and innovation leader with a strong scientific background and extensive experience in research, drug development, and commercialization. As CEO of Yeda, he leads the translation of Weizmann Institute discoveries into real-world impactful applications through licensing, strategic partnerships, and venture creation. Previously, he served as VP of Business Development at Yeda and held senior roles at Quark Pharmaceuticals and Teva Pharmaceuticals. Elik holds a Ph.D. in Molecular Genetics and an M.Sc. in Developmental Biology from the Weizmann Institute. His blend of scientific expertise with strategic vision and business acumen drives Yeda’s mission forward.